Rare diseases are frequently life-threatening, chronic illnesses. A rare disease is defined by the World Health Organization as a debilitating lifelong disease or disorder with a prevalence of 1 or less per 1000 people. Different countries, on the other hand, have their own definitions tailored to their individual needs and in the context of their population, health-care system, and resources. Medications developed specifically to treat rare disorders, known as "orphan drugs," are frequently left underdeveloped economically because of the minimal prospect for profit. Rare Diseases and Orphan Drugs demonstrates that studying rare diseases has led to much of what we currently know about common diseases. It posits that our rapid development in the field of rare diseases will lead to future advancements in the prevention, diagnosis, and treatment of common diseases. Rare disorders, on the other hand, are frequently caused by mutations in a single gene.
Title : Copper (II) complexes as potential anticancer agents
Salah S Massoud, University of Louisiana, United States
Title : Pharmacogenomics: current status and future directions
Matthias Schwab, University of Tübingen, Germany
Title : Talus bone of the hindfoot: Unique anatomy and an important clinical implication
Abdelmonem Awad Hegazy, Zarqa University, Jordan
Title : The use of anti seizure medication therapeutic blood level determination to personalise the treatment of epileptic seizures especially in patients attending the accident and emergency department
Roy Gary Beran, University of New South Wales, Australia
Title : Effect of Fluvoxamine on Interluekin-6 level of COVID-19 patients, hospitalized in ICU: A randomized clinical trial
Mitra Safa, Shahid Beheshti University of Medical Sciences, Iran (Islamic Republic of)
Title : Precision Treatment of Alzheimer's
Boris Tankhilevich, Magtera, Inc., United States